{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:28:43Z","timestamp":1788618523937,"version":"build-2803163510"},"reference-count":61,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR132803"],"award-info":[{"award-number":["NIHR132803"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2024,4,1]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Migraine is the second most common prevalent disorder worldwide and is a top cause of disability with a substantial economic burden. Many preventive migraine medications have notable side effects that affect different body organs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>We systematically searched for published randomised controlled trials (RCTs) using terms for migraine\/headache and preventive medications. Using eligibility criteria, two reviewers independently assessed the articles. Cochrane risk-of-bias tool was applied to assess the quality of the studies. Data were classified by system organ class (SOC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-two RCTs with 21\u2009780 participants met the eligibility criteria for the incidence of adverse events (AEs). Additionally, 33 RCTs with 22\u2009615 participants were included to synthesise the incidence of serious AEs (SAEs). The percentage of attributed AEs and SAEs to each SOC for 10 preventive drugs with different dosing regimens was calculated. Amitriptyline and topiramate had a higher incidence of nervous system disorders; Topiramate was also associated with a higher incidence of psychiatric disorders. All drugs showed a certain incidence of infections and infestations, with Onabotulinumtoxin A (BTA) having the lowest rate. BTA had a higher incidence of musculoskeletal disorders than the other drugs. Calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) such as fremanezumab and galcanezumab were linked to more general disorders and administration site conditions than other drugs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Notably, the observed harm to SOCs varies among these preventive drugs. We suggest conducting head-to-head RCTs to evaluate the safety profile of oral medications, BTA, and CGRP MAbs in episodic and\/or chronic migraine populations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD42021265993.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjno-2023-000616","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T12:40:26Z","timestamp":1713357626000},"page":"e000616","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5504-7189","authenticated-orcid":false,"given":"Seyran","family":"Naghdi","sequence":"first","affiliation":[{"name":"Warwick Clinical Trials Unit, University of Warwick, Warwick Medical School, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Underwood","sequence":"additional","affiliation":[{"name":"Warwick Clinical Trials Unit, University of Warwick, Warwick Medical School, Coventry, UK"},{"name":"University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Brown","sequence":"additional","affiliation":[{"name":"Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjit","family":"Matharu","sequence":"additional","affiliation":[{"name":"Headache Group, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4516-9024","authenticated-orcid":false,"given":"Callum","family":"Duncan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Aberdeen Royal Infirmary, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Davies","sequence":"additional","affiliation":[{"name":"Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiva","family":"Aksentyte","sequence":"additional","affiliation":[{"name":"Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5023-1160","authenticated-orcid":false,"given":"Hema","family":"Mistry","sequence":"additional","affiliation":[{"name":"Warwick Clinical Trials Unit, University of Warwick, Warwick Medical School, Coventry, UK"},{"name":"University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"2025072812154843000_6.1.e000616.1","doi-asserted-by":"crossref","unstructured":"Khanal S , Underwood M , Naghdi S , et al . A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine. J Headache Pain 2022;23. doi:10.1186\/s10194-022-01492-y","DOI":"10.1186\/s10194-022-01492-y"},{"key":"2025072812154843000_6.1.e000616.2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40263-020-00715-7","article-title":"Safety and efficacy of Ubrogepant for the acute treatment of episodic migraine: a meta-analysis of randomized clinical trials","volume":"34","author":"Yang","year":"2020","journal-title":"CNS Drugs"},{"key":"2025072812154843000_6.1.e000616.3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40273-020-00996-2","article-title":"Cost-effectiveness of Erenumab for the preventive treatment of migraine in patients with prior treatment failures in Sweden","volume":"39","author":"Mahon","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"2025072812154843000_6.1.e000616.4","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40120-022-00370-8","article-title":"Atogepant for the prevention of episodic migraine in adults: A systematic review and meta-analysis of efficacy and safety","volume":"11","author":"Lattanzi","year":"2022","journal-title":"Neurol Ther"},{"key":"2025072812154843000_6.1.e000616.5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/head.13498","article-title":"Patient preferences for preventive migraine treatments: a Discrete\u2010Choice experiment","volume":"59","author":"Mansfield","year":"2019","journal-title":"Headache"},{"key":"2025072812154843000_6.1.e000616.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01431.x"},{"key":"2025072812154843000_6.1.e000616.7","doi-asserted-by":"crossref","unstructured":"Herd CP , Tomlinson CL , Rick C , et al . Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev 2018;6. doi:10.1002\/14651858.CD011616.pub2","DOI":"10.1002\/14651858.CD011616.pub2"},{"key":"2025072812154843000_6.1.e000616.8","doi-asserted-by":"crossref","unstructured":"Hou M , Xing H , Cai Y , et al . The effect and safety of Monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. J Headache Pain 2017;18. doi:10.1186\/s10194-017-0750-1","DOI":"10.1186\/s10194-017-0750-1"},{"key":"2025072812154843000_6.1.e000616.9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01069-1"},{"key":"2025072812154843000_6.1.e000616.10","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018483","article-title":"Erenumab safety and efficacy in migraine: a systematic review and meta-analysis of randomized clinical trials","volume":"98","author":"Zhu","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2025072812154843000_6.1.e000616.11","doi-asserted-by":"crossref","unstructured":"Gao B , Yang Y , Wang Z , et al . Efficacy and safety of Rimegepant for the acute treatment of migraine: evidence from randomized controlled trials. Front Pharmacol 2019;10. doi:10.3389\/fphar.2019.01577","DOI":"10.3389\/fphar.2019.01577"},{"key":"2025072812154843000_6.1.e000616.12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40261-022-01130-0","article-title":"Atogepant for migraine prevention: a systematic review of efficacy and safety","volume":"42","author":"Singh","year":"2022","journal-title":"Clin Drug Investig"},{"key":"2025072812154843000_6.1.e000616.13","first-page":"938","article-title":"Therapeutic effects and safety of Olcegepant and Telcagepant for migraine: A meta-analysis","volume":"8","author":"Yao","year":"2013","journal-title":"Neural Regen Res"},{"key":"2025072812154843000_6.1.e000616.14","doi-asserted-by":"crossref","unstructured":"Wang X , Chen Y , Song J , et al . Efficacy and safety of Monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis. Front Pharmacol 2021;12. doi:10.3389\/fphar.2021.649143","DOI":"10.3389\/fphar.2021.649143"},{"key":"2025072812154843000_6.1.e000616.15","doi-asserted-by":"crossref","unstructured":"Page MJ , McKenzie JE , Bossuyt PM , et al . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 2021;10. doi:10.1186\/s13643-021-01626-4","DOI":"10.1186\/s13643-021-01626-4"},{"key":"2025072812154843000_6.1.e000616.16","doi-asserted-by":"publisher","DOI":"10.5195\/jmla.2021.1260"},{"key":"2025072812154843000_6.1.e000616.17","unstructured":"US Department of health human services, common terminology criteria for adverse events (CTCAE) version 5.0."},{"key":"2025072812154843000_6.1.e000616.18","doi-asserted-by":"crossref","unstructured":"Sterne JAC , Savovi\u0107 J , Page MJ , et al . Rob 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366. doi:10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"2025072812154843000_6.1.e000616.19","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/head.14178","article-title":"Efficacy and safety of Fremanezumab for episodic migraine prevention: multicenter, randomized, Double\u2010Blind, Placebo\u2010Controlled, Parallel\u2010Group trial in Japanese and Korean patients","volume":"61","author":"Sakai","year":"2021","journal-title":"Headache"},{"key":"2025072812154843000_6.1.e000616.20","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/head.14169","article-title":"Efficacy and safety of Fremanezumab for chronic migraine prevention: multicenter, randomized, Double\u2010Blind, Placebo\u2010Controlled, Parallel\u2010Group trial in Japanese and Korean patients","volume":"61","author":"Sakai","year":"2021","journal-title":"Headache"},{"key":"2025072812154843000_6.1.e000616.21","doi-asserted-by":"crossref","unstructured":"Sakai F , Ozeki A , Skljarevski V . Efficacy and safety of Galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: a phase 2 randomized controlled clinical trial. Cephalalgia Reports 2020;3. doi:10.1177\/2515816320932573","DOI":"10.1177\/2515816320932573"},{"key":"2025072812154843000_6.1.e000616.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"key":"2025072812154843000_6.1.e000616.23","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410364677"},{"key":"2025072812154843000_6.1.e000616.24","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410364676"},{"key":"2025072812154843000_6.1.e000616.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01678.x"},{"key":"2025072812154843000_6.1.e000616.26","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of Eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"2025072812154843000_6.1.e000616.27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/head.14036","article-title":"Efficacy, tolerability, and safety of Eptinezumab in patients with a dual diagnosis of chronic migraine and Medication\u2010Overuse headache: subgroup analysis of PROMISE\u20102","volume":"61","author":"Diener","year":"2021","journal-title":"Headache"},{"key":"2025072812154843000_6.1.e000616.28","doi-asserted-by":"crossref","unstructured":"Silberstein S , Diamond M , Hindiyeh NA , et al . Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (prevention of migraine via intravenous Ald403 safety and Efficacy\u20132) study. J Headache Pain 2020;21. doi:10.1186\/s10194-020-01186-3","DOI":"10.1186\/s10194-020-01186-3"},{"key":"2025072812154843000_6.1.e000616.29","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"2025072812154843000_6.1.e000616.30","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419858355"},{"key":"2025072812154843000_6.1.e000616.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"2025072812154843000_6.1.e000616.32","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1177\/0333102418788347","article-title":"Efficacy and safety of Erenumab (Amg334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"38","author":"Ashina","year":"2018","journal-title":"Cephalalgia"},{"key":"2025072812154843000_6.1.e000616.33","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","article-title":"Erenumab in chronic migraine with medication Overuse: subgroup analysis of a randomized trial","volume":"92","author":"Tepper","year":"2019","journal-title":"Neurology"},{"key":"2025072812154843000_6.1.e000616.34","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3B trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"The Lancet"},{"key":"2025072812154843000_6.1.e000616.35","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/head.13653","article-title":"FORWARD study: evaluating the comparative effectiveness of onabotulinumtoxinA and Topiramate for headache prevention in adults with chronic migraine","volume":"59","author":"Rothrock","year":"2019","journal-title":"Headache"},{"key":"2025072812154843000_6.1.e000616.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035908"},{"key":"2025072812154843000_6.1.e000616.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00019-3"},{"key":"2025072812154843000_6.1.e000616.38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"2025072812154843000_6.1.e000616.39","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70128-0"},{"key":"2025072812154843000_6.1.e000616.40","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"2025072812154843000_6.1.e000616.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.03.020"},{"key":"2025072812154843000_6.1.e000616.42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4853"},{"key":"2025072812154843000_6.1.e000616.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"2025072812154843000_6.1.e000616.44","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"key":"2025072812154843000_6.1.e000616.45","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"2025072812154843000_6.1.e000616.46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/03331024211053571","article-title":"Erenumab versus Topiramate for the prevention of migraine\u2013a randomised, double-blind, active-controlled phase 4 trial","volume":"42","author":"Reuter","year":"2022","journal-title":"Cephalalgia"},{"key":"2025072812154843000_6.1.e000616.47","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of Erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3B study","volume":"392","author":"Reuter","year":"2018","journal-title":"The Lancet"},{"key":"2025072812154843000_6.1.e000616.48","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1177\/03331024211024160","article-title":"Randomised, controlled trial of Erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: the empower study","volume":"41","author":"Wang","year":"2021","journal-title":"Cephalalgia"},{"key":"2025072812154843000_6.1.e000616.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2006.03.002"},{"key":"2025072812154843000_6.1.e000616.50","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30279-9"},{"key":"2025072812154843000_6.1.e000616.51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral Rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop","year":"2021","journal-title":"The Lancet"},{"key":"2025072812154843000_6.1.e000616.52","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1001\/jama.2021.7665","article-title":"Effects of intravenous Eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial","volume":"325","author":"Winner","year":"2021","journal-title":"JAMA"},{"key":"2025072812154843000_6.1.e000616.53","doi-asserted-by":"crossref","unstructured":"Hu B , Li G , Li X , et al . Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study. J Headache Pain 2022;23. doi:10.1186\/s10194-022-01458-0","DOI":"10.1186\/s10194-022-01458-0"},{"key":"2025072812154843000_6.1.e000616.54","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","article-title":"Safety and efficacy of Eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3B trial","volume":"21","author":"Ashina","year":"2022","journal-title":"Lancet Neurol"},{"key":"2025072812154843000_6.1.e000616.55","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/head.14439","article-title":"Once\u2010Daily oral Atogepant for the Long\u2010Term preventive treatment of migraine: findings from a multicenter, randomized, Open\u2010Label, phase 3 trial","volume":"63","author":"Ashina","year":"2023","journal-title":"Headache"},{"key":"2025072812154843000_6.1.e000616.56","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/head.14138","article-title":"Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a phase 3, randomized, Double\u2010Blind, Placebo\u2010Controlled study","volume":"61","author":"Takeshima","year":"2021","journal-title":"Headache"},{"key":"2025072812154843000_6.1.e000616.57","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-022-01514-9","article-title":"A phase 3, randomised, placebo-controlled study of Erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study","volume":"23","author":"Yu","year":"2022","journal-title":"J Headache Pain"},{"key":"2025072812154843000_6.1.e000616.58","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30085-1"},{"key":"2025072812154843000_6.1.e000616.59","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s40263-021-00834-9","article-title":"Indirect comparison of topiramate and Monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis","volume":"35","author":"Overeem","year":"2021","journal-title":"CNS Drugs"},{"key":"2025072812154843000_6.1.e000616.60","doi-asserted-by":"crossref","unstructured":"Gao B , Sun N , Yang Y , et al . Safety and efficacy of Fremanezumab for the prevention of migraine: a meta-analysis from randomized controlled trials. Front Neurol 2020;11. doi:10.3389\/fneur.2020.00435","DOI":"10.3389\/fneur.2020.00435"},{"key":"2025072812154843000_6.1.e000616.61","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an oral calcitonin gene\u2013related peptide receptor antagonist, for migraine","volume":"381","author":"Lipton","year":"2019","journal-title":"N Engl J Med"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2023-000616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T19:16:25Z","timestamp":1753730185000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2023-000616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,4,17]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/bmjno-2023-000616"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2023-000616","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}